Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HikalNSE:HIKAL +0.33%72 EV-to-FCF is 43.61 as of Sep. 22, 2026. GuruFocus rates NSE:HIKAL with a GF Score™ of 72/100 and a GF Value™ of ₹272.98 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 573 Drug Manufacturers companies, Hikal ranks worse than 54.45% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hikal's Enterprise Value is ₹34,580 Mil.
Hikal's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ₹793 Mil. Therefore, Hikal's EV-to-FCF for today is 43.61.
The historical rank and industry rank for Hikal's EV-to-FCF or its related term are showing as below:
NSE:HIKAL'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 22.37
Current: 22.37
During the past 13 years, the highest EV-to-FCF of Hikal was 22.37. The lowest was 0.00. And the median was 0.00.
NSE:HIKAL's EV-to-FCF is ranked worse than 54.45% of 573
companies
in the Drug Manufacturers industry
Industry Median: 19.25
vs NSE:HIKAL: 22.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-22), Hikal's stock price is ₹227.00.
Hikal's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-2.741. Therefore, Hikal's PE Ratio (TTM) for today is At Loss.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hikal's share price for today is ₹227.00.
Hikal's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2.741.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hikal EV-to-FCF Related Terms
Hikal EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Hikal's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikal's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikal EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikal's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hikal's EV-to-FCF falls into.
Hikal's current Enterprise Value is ₹34,580 Mil.
Hikal's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹793 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikal (NSE:HIKAL) has a EV-to-FCF of 43.61 as of Sep. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hikal and its competitors. According to the industry distribution chart, Hikal ranks #312 out of 573 companies in the Drug Manufacturers industry, placing it in the top 54.5%.
Is Hikal's EV-to-FCF too high?
Hikal's current EV-to-FCF is 43.61. The Drug Manufacturers industry median EV-to-FCF is 19.25. Hikal's value of 43.61 is 126.5% above this industry median. Based on the distribution chart, Hikal ranks #312 out of 573 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hikal has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikal's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hikal ranks #312 out of 573 companies for EV-to-FCF. This places Hikal in the lower half of its industry. The industry median EV-to-FCF is 19.25. Hikal's value of 43.61 is 126.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.25, based on 573 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikal's current EV-to-FCF of 43.61 is 126.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hikal and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikal's current EV-to-FCF is 43.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikal stock overvalued right now?
Based on GuruFocus' analysis, Hikal (NSE:HIKAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹272.98, compared to a current price of ₹227.00 — trading 16.8% below its estimated fair value. The current EV-to-FCF is 43.61 and 126.5% above the Drug Manufacturers industry median of 19.25. Hikal's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hikal (NSE:HIKAL), the current EV-to-FCF is 43.61 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikal (NSE:HIKAL) Overvalued in 2026?
Based on GuruFocus' analysis, Hikal stock appears to be undervalued.
The current stock price of ₹227.00 is trading 16.8% below its estimated GF Value™ of ₹272.98.
GuruFocus considers Hikal to be Modestly Undervalued.
Key valuation signals for NSE:HIKAL:
EV-to-FCF: 43.61
GF Value™: ₹272.98 vs. price of ₹227.00 (16.8% below fair value)
Industry Position: 126.5% above the Drug Manufacturers median (#312 of 573)
No single metric tells the full story. See the NSE:HIKAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikal Ltd is an Indian manufacturer of active pharmaceutical ingredients (APIs) and crop protection chemicals, operating through two segments: Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces APIs, advanced intermediates, and custom manufacturing services for pharmaceutical customers, while the Crop Protection segment manufactures pesticides, herbicides, and their active ingredients and intermediates. The company also provides contract research and development and contract manufacturing services to innovator pharmaceutical and agrochemical companies. Its customers include global pharmaceutical and crop science companies, and it serves markets across India, Europe, North America, and other regions, with Europe historically a major contributor to revenue. Hikal operates manufacturing facilities in India and generates revenue primarily through product sales and custom manufacturing arrangements with long-term customer contracts.
72GF Score
Get the complete analysis for NSE:HIKAL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HIKAL has been successfully added to your 
